Gufic Biosciences rises on getting DCGI nod for Thymosin Alpha-1

06 Apr 2022 Evaluate

Gufic Biosciences is currently trading at Rs. 263.15, up by 4.20 points or 1.62% from its previous closing of Rs. 258.95 on the BSE.

The scrip opened at Rs. 264.50 and has touched a high and low of Rs. 264.80 and Rs. 260.60 respectively. So far 6561 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 271.30 on 05-Apr-2022 and a 52 week low of Rs. 107.60 on 12-Apr-2021.

Last one week high and low of the scrip stood at Rs. 271.30 and Rs. 247.40 respectively. The current market cap of the company is Rs. 2510.38 crore.

The promoters holding in the company stood at 75.48%, while Institutions and Non-Institutions held 2.88% and 21.64% respectively.

Gufic Biosciences has received DCGI approval for Thymosin Alpha-1 (Immunocin - A Brand of Gufic for the said drug) as an add-on therapy for the treatment of moderate-to-severe COVID-19 patients requiring ventilator support (NIV as well as Mechanical Ventilation). Immunocin, an Immuno-modulator drug, significantly reduced the risk of death in the Phase 3 Clinical trial in adult patients with moderate-to-severe COVID-19.

Gufic Biosciences is engaged in diversified business viz. Pharma, Healthcare, Bio- Technology, Seeds, Herbal etc.

Gufic Biosciences Share Price

321.80 -4.40 (-1.35%)
15-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1528.20
Dr. Reddys Lab 5872.35
Cipla 1405.95
Zydus Lifesciences 997.45
Lupin 1638.40
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.